X4 Pharmaceuticals Prepares for Third-Quarter Financial Update
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR), a company dedicated to transforming the lives of individuals with rare immune system diseases, has announced an upcoming conference call and webcast. This event is significant as it will cover both the financial results for the third quarter and the findings from a Phase 2 clinical study evaluating mavorixafor, a promising treatment for chronic neutropenia.
Details of the Conference Call
The conference call is scheduled for 8:00 a.m. ET. Participants can join by dialing either 1-800-267-6316 within the United States or 1-203-518-9783 from international locations, using the conference ID: X4PHARMA. Those interested can also watch the live webcast, which includes a slide presentation. This will be available through the investor relations section of X4 Pharmaceuticals’ website.
Accessing the Replay
After the conclusion of the conference call, a replay will be made accessible on the company’s website, allowing stakeholders and interested parties to catch up on what they may have missed during the live broadcast.
About X4 Pharmaceuticals and Its Mission
X4 Pharmaceuticals is at the forefront of pharmaceutical development, aiming to improve treatments for patients facing rare diseases linked to the immune system. By leveraging an in-depth understanding of CXCR4 biology, the company has successfully brought mavorixafor to market under the brand name XOLREMDI (mavorixafor) capsules, marking a significant achievement in its first approved indication.
Expansion of Mavorixafor's Applications
Beyond its initial approval, X4 Pharmaceuticals is exploring new possibilities for mavorixafor across various medical indications. This strategic focus aims to meet the significant unmet needs of patients requiring effective therapies to manage their health conditions.
Company Background Information
X4 Pharmaceuticals operates from its corporate headquarters in Boston, Massachusetts, alongside a research center of excellence located in Vienna, Austria. This combination of locations underscores the company’s commitment to advancing its research and development efforts to address gaps in treatment options for rare diseases.
Reaching Out for More Information
For individuals looking to delve deeper into X4 Pharmaceuticals and its initiatives, further details are available on the company’s website.
Frequently Asked Questions
What is the main purpose of the upcoming conference call?
The conference call is intended to report the third-quarter financial results and share findings from a Phase 2 clinical trial related to chronic neutropenia.
How can I participate in the conference call?
Participation can be achieved by calling 1-800-267-6316 in the U.S. or 1-203-518-9783 internationally, using the conference ID: X4PHARMA.
When will the replay of the conference call be available?
A replay of the call will be available after the live event on X4 Pharmaceuticals’ website.
What is mavorixafor?
Mavorixafor is a therapy developed by X4 Pharmaceuticals, initially approved as XOLREMDI for treating certain immune system-related diseases.
Where is X4 Pharmaceuticals headquartered?
The company's headquarters is located in Boston, Massachusetts, with a significant research center in Vienna, Austria.
